Erlotinib protects against LPS-induced endotoxicity because TLR4 needs EGFR to signal

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 31, 2015, Pages 9680-9685

  De, Sarmishtha ^a   Zhou, Hao ^a   DeSantis, David ^b   Croniger, Colleen M ^b   Li, Xiaoxia ^a   Stark, George R ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

EGFR; Erlotinib; LPS; NF B; TLR4

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN KINASE LYN; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; LYN PROTEIN-TYROSINE KINASE; MAP KINASE KINASE KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; PROTECTIVE AGENT; PROTEIN TYROSINE KINASE; QUINAZOLINE DERIVATIVE; TLR4 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; ENDOTOXICITY; GENE SILENCING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TOXICITY; ANIMAL; CELL LINE; DRUG EFFECTS; METABOLISM; PHOSPHORYLATION;

MUS;

ANIMALS; CELL LINE; CYTOKINES; EPIDERMAL GROWTH FACTOR; ERLOTINIB HYDROCHLORIDE; GENE SILENCING; HUMANS; LIPOPOLYSACCHARIDES; MAP KINASE KINASE KINASES; MICE; MYELOID DIFFERENTIATION FACTOR 88; NF-KAPPA B; PHOSPHORYLATION; PROTECTIVE AGENTS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84938674582     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1511794112     Document Type: Article

References (59)

1. Hayden MS, Ghosh S (2008) Shared principles in NF-kappaB signaling. Cell 132(3): 344-362.
2. Hoffmann A, Baltimore D (2006) Circuitry of nuclear factor kappaB signaling. Immunol Rev 210:171-186.
3. Brown M, Cohen J, Arun P, Chen Z, Van Waes C (2008) NF-kappaB in carcinoma therapy and prevention. Expert Opin Ther Targets 12(9):1109-1122.
4. De S, Dermawan JK, Stark GR (2014) EGF receptor uses SOS1 to drive constitutive activation of NFκB in cancer cells. Proc Natl Acad Sci USA 111(32):11721-11726.
5. Hayden MS, Ghosh S (2004) Signaling to NF-kappaB. Genes Dev 18(18):2195-2224.
6. Gilmore TD (2006) Introduction to NF-kappaB: Players, pathways, perspectives. Oncogene 25(51):6680-6684.
7. Oeckinghaus A, Ghosh S (2009) The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol 1(4):a000034.
8. Morandell S, Stasyk T, Skvortsov S, Ascher S, Huber LA (2008) Quantitative proteomics and phosphoproteomics reveal novel insights into complexity and dynamics of the EGFR signaling network. Proteomics 8(21):4383-4401.
9. Okamoto I (2010) Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy. FEBS J 277(2):309-315.
10. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298(5600):1912-1934.
11. Ingley E (2008) Src family kinases: Regulation of their activities, levels and identification of new pathways. Biochim Biophys Acta 1784(1):56-65.
12. Parsons SJ, Parsons JT (2004) Src family kinases, key regulators of signal transduction. Oncogene 23(48):7906-7909.
13. Kawai T, Akira S (2007) Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med 13(11):460-469.
14. O'Neill LA, Bowie AG (2007) The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 7(5):353-364.
15. Janeway CA, Jr, Medzhitov R (2002) Innate immune recognition. Annu Rev Immunol 20:197-216.
16. Akira S, Uematsu S, Takeuchi O (2006) Pathogen recognition and innate immunity. Cell 124(4):783-801.
17. Akira S, Hemmi H (2003) Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett 85(2):85-95.
18. Rakoff-Nahoum S, Medzhitov R (2009) Toll-like receptors and cancer. Nat Rev Cancer 9(1):57-63.
19. Koff JL, Shao MX, Ueki IF, Nadel JA (2008) Multiple TLRs activate EGFR via a signaling cascade to produce innate immune responses in airway epithelium. Am J Physiol Lung Cell Mol Physiol 294(6):L1068-L1075.
20. Yamashita M, et al. (2012) Epidermal growth factor receptor is essential for Toll-like receptor 3 signaling. Sci Signal 5(233):ra50.
21. Medzhitov R, Janeway C, Jr (2000) Innate immunity. N Engl J Med 343(5):338-344.
22. Stoll LL, Denning GM, Weintraub NL (2006) Endotoxin, TLR4 signaling and vascular inflammation: Potential therapeutic targets in cardiovascular disease. Curr Pharm Des 12(32):4229-4245.
23. Lu YC, Yeh WC, Ohashi PS (2008) LPS/TLR4 signal transduction pathway. Cytokine 42(2):145-151.
24. Akira S (2003) Toll-like receptor signaling. J Biol Chem 278(40):38105-38108.
25. Akira S, Takeda K (2004) Toll-like receptor signalling. Nat Rev Immunol 4(7):499-511.
26. Ferrantini M, Capone I, Belardelli F (2008) Dendritic cells and cytokines in immune rejection of cancer. Cytokine Growth Factor Rev 19(1):93-107.
27. Khatami M (2005) Developmental phases of inflammation-induced massive lymphoid hyperplasia and extensive changes in epithelium in an experimental model of allergy: Implications for a direct link between inflammation and carcinogenesis. Am J Ther 12(2):117-126.
28. Khatami M (2008) 'Yin and Yang' in inflammation: Duality in innate immune cell function and tumorigenesis. Expert Opin Biol Ther 8(10):1461-1472.
29. Smyth MJ, Godfrey DI, Trapani JA (2001) A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2(4):293-299.
30. Hsu D, et al. (2010) Toll-like receptor 4 differentially regulates epidermal growth factor-related growth factors in response to intestinal mucosal injury. Lab Invest 90(9):1295-1305.
31. Shuyi Y, et al. (2011) Human beta-defensin-3 (hBD-3) upregulated by LPS via epidermal growth factor receptor (EGFR) signaling pathways to enhance lymphatic invasion of oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 112(5):616-625.
32. McElroy SJ, et al. (2012) Transactivation of EGFR by LPS induces COX-2 expression in enterocytes. PLoS One 7(5):e38373.
33. Hattar K, et al. (2013) Endotoxin induces proliferation of NSCLC in vitro and in vivo: Role of COX-2 and EGFR activation. Cancer Immunol Immunother 62(2):309-320.
34. Trussoni CE, Tabibian JH, Splinter PL, O'Hara SP (2015) Lipopolysaccharide (LPS)-Induced Biliary Epithelial Cell NRas Activation Requires Epidermal Growth Factor Receptor (EGFR). PLoS One 10(4):e0125793.
35. Cohen J (2002) The immunopathogenesis of sepsis. Nature 420(6917):885-891.
36. Doi K, Leelahavanichkul A, Yuen PS, Star RA (2009) Animal models of sepsis and sepsis-induced kidney injury. J Clin Invest 119(10):2868-2878.
37. McNamara MJ, Norton JA, Nauta RJ, Alexander HR (1993) Interleukin-1 receptor antibody (IL-1rab) protection and treatment against lethal endotoxemia in mice. J Surg Res 54(4):316-321.
38. Tracey KJ, et al. (1987) Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330(6149):662-664.
39. Fisher CJ, Jr, et al.; The Soluble TNF Receptor Sepsis Study Group (1996) Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. N Engl J Med 334(26):1697-1702.
40. Fisher CJ, Jr, et al. (1994) Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 271(23):1836-1843.
41. Medzhitov R, Janeway CA, Jr (1998) Innate immune recognition and control of adaptive immune responses. Semin Immunol 10(5):351-353.
42. Takaesu G, et al. (2003) TAK1 is critical for IkappaB kinase-mediated activation of the NF-kappaB pathway. J Mol Biol 326(1):105-115.
43. Medvedev AE, et al. (2007) Role of TLR4 tyrosine phosphorylation in signal transduction and endotoxin tolerance. J Biol Chem 282(22):16042-16053.
44. Fiorotto R, et al. (2011) Loss of CFTR affects biliary epithelium innate immunity and causes TLR4-NF-kappaB-mediated inflammatory response in mice. Gastroenterology 141(4):1498-1508. e1491-1495.
45. Wu W, Graves LM, Gill GN, Parsons SJ, Samet JM (2002) Src-dependent phosphorylation of the epidermal growth factor receptor on tyrosine 845 is required for zincinduced Ras activation. J Biol Chem 277(27):24252-24257.
46. Sutton P, Borgia JA, Bonomi P, Plate JM (2013) Lyn, a Src family kinase, regulates activation of epidermal growth factor receptors in lung adenocarcinoma cells. Mol Cancer 12:76.
47. Avila M, Martinez-Juarez A, Ibarra-Sanchez A, Gonzalez-Espinosa C (2012) Lyn kinase controls TLR4-dependent IKK and MAPK activation modulating the activity of TRAF-6/TAK-1 protein complex in mast cells. Innate Immun 18(4):648-660.
48. Janssens S, Beyaert R (2002) A universal role for MyD88 in TLR/IL-1R-mediated signaling. Trends Biochem Sci 27(9):474-482.
49. Irie T, Muta T, Takeshige K (2000) TAK1 mediates an activation signal from toll-like receptor(s) to nuclear factor-kappaB in lipopolysaccharide-stimulated macrophages. FEBS Lett 467(2-3):160-164.
50. Stover DR, Becker M, Liebetanz J, Lydon NB (1995) Src phosphorylation of the epidermal growth factor receptor at novel sites mediates receptor interaction with Src and P85 alpha. J Biol Chem 270(26):15591-15597.
51. Biscardi JS, et al. (1999) c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J Biol Chem 274(12):8335-8343.
52. Biscardi JS, Ishizawar RC, Silva CM, Parsons SJ (2000) Tyrosine kinase signalling in breast cancer: Epidermal growth factor receptor and c-Src interactions in breast cancer. Breast Cancer Res 2(3):203-210.
53. Lin WN, et al. (2007) Involvement of MAPKs and NF-kappaB in LPS-induced VCAM-1 expression in human tracheal smooth muscle cells. Cell Signal 19(6):1258-1267.
54. Lin WN, Luo SF, Wu CB, Lin CC, Yang CM (2008) Lipopolysaccharide induces VCAM-1 expression and neutrophil adhesion to human tracheal smooth muscle cells: Involvement of Src/EGFR/PI3-K/Akt pathway. Toxicol Appl Pharmacol 228(2):256-268.
55. Finzi L, Shao MX, Paye F, Housset C, Nadel JA (2009) Lipopolysaccharide initiates a positive feedback of epidermal growth factor receptor signaling by prostaglandin E2 in human biliary carcinoma cells. J Immunol 182(4):2269-2276.
56. Basu S, et al. (2008) Helicobacter pylori protein HP0175 transactivates epidermal growth factor receptor through TLR4 in gastric epithelial cells. J Biol Chem 283(47):32369-32376.
57. Henricson BE, Carboni JM, Burkhardt AL, Vogel SN (1995) LPS and Taxol activate Lyn kinase autophosphorylation in Lps(n), but not in Lpsd), macrophages. Mol Med 1(4):428-435.
58. Miyake K (2004) Innate recognition of lipopolysaccharide by Toll-like receptor 4-MD-2. Trends Microbiol 12(4):186-192.
59. Shimizu K, et al. (2012) Hepatocyte growth factor inhibits lipopolysaccharide-induced oxidative stress via epithelial growth factor receptor degradation. Arterioscler Thromb Vasc Biol 32(11):2687-2693.